Philadelphia — Dr. Henry Daniell, Professor and Interim Chair of Biochemistry and Director of Translational Research at Penn Dental Medicine, has been recognized by the American Heart Association with an award for the top basic science paper published in the journal Hypertension in 2014. The award was presented by Dr. Anna Dominicizak, Editor-in-Chief of _Hypertension_, at the Council of Hypertension 2015, held Sept. 16–19, 2015, in Washington, D.C.
The paper reported on a study conducted by Dr. Daniell and collaborators from the University of Florida that identified a drug that can be used to treat pulmonary hypertension, a disease for which few therapy options exist. The novelty is the way the medicine is produced and delivered – grown in the leaves of plants within Dr. Daniell’s high-tech greenhouse, then bio-encapsulated, and taken orally.
Dr. Daniell was a senior author on the study. Fellow Penn Dental Medicine authors included postdoctoral associate Kwang Chul-Kwon and research assistants Shina Lin and Guiying Jin. The Penn team collaborated with researchers from the University of Florida, including Vinayak Shenoy, an assistant research scientist in the College of Pharmacy Department of Pharmacodynamics; co-senior author Mohan Raizada, a distinguished professor of physiology and functional genomics in the Evelyn F. and William L. McKnight Brain Institute; and Michael Katovich, a professor in the College of Pharmacy.
In patients with pulmonary hypertension, the arteries of the lungs become constricted, which increases the workload on the right side of the heart to pump blood through the lungs. Over time, the right chamber of the heart, which usually is small, becomes enlarged and dysfunctional.
Blood pressure is regulated by a hormonal system called the renin-angiotensin system. Too much of a key hormone in this system, angiotensin II, can raise blood pressure. However, angiotensin II is balanced by two other proteins, ACE 2 and Ang-(1-7), that maintain normal cardiopulmonary pressure, according to previous research by the UF researchers.
Their studies have shown that increasing the amount of these hormones in the body prevents pulmonary hypertension. But the researchers needed an effective way to deliver these proteins to test their therapeutic potential. Because the hormones are already found in the human body, Raizada said, they had little concern about potential side effects.
“All of the drugs on the market so far for hypertension and cardiovascular diseases are based on inhibiting angiotensin II and aren’t very effective,” Dr. Raizada said. “Many years ago, we began to question why the prevalence of hypertension and cardiopulmonary diseases does not decrease when you inhibit angiotensin II. Instead, we thought we should be targeting the hormones that balance angiotensin II.”
Dr. Daniell studies protein drug delivery using plants and introduced genes with the ACE 2 and Ang-(1-7) proteins into plant chloroplasts, which then could be grown, freeze-dried, enclosed in capsules and fed to rats. Plant cells protect protein drugs from acids and enzymes in the stomach, but drugs are released in the gut for absorption when bacteria in the gut digest the plant cell walls. To make sure the proteins could travel across the intestinal wall and into the bloodstream, they were fused with a protein that binds to intestinal cells.
“The proteins we were dealing with are very large and unstable, only lasting a few minutes in the bloodstream when given as an injection,” Dr. Daniell said. “We needed to find a way to stabilize the proteins to increase their lifespan in the bloodstream and make sure it was working the way we wanted it to.”
“Most importantly, current cost of treatment ranges between $60-200,000/year per patient, with a sub-optimal survival of 55% after three years,” Daniell said. “So, it is important to find a low cost drug delivered at patient’s convenience and this study has opened a new option for an effective and affordable treatment.”
When patients are treated with other medications, they typically see only a slight improvement — about a 10 percent reduction in pulmonary pressure. After the rats with established pulmonary hypertension had been treated with the medication for two weeks, their pulmonary pressure was reduced by 20 percent. After four weeks of using the plant-delivered medication to treat a group of 8-10 rats with pulmonary hypertension, the researchers found that the medication reduced pulmonary pressure by 32 percent.
Though pulmonary hypertension causes vessels in the lungs to constrict, patients actually die from heart failure. But the drug also improved function on the right side of the heart, potentially avoiding heart failure in patients, Dr. Shenoy said.
Next, they hope to test the drug in clinical trials.